This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are You Looking for a Top Momentum Pick? Why Syndax Pharmaceuticals (SNDX) is a Great Choice
by Zacks Equity Research
Does Syndax Pharmaceuticals (SNDX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Syndax Pharmaceuticals (SNDX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $26.46, marking a +0.57% move from the previous day.
Incyte (INCY) Up 7% in a Year: Will the Momentum Continue?
by Zacks Equity Research
Incyte (INCY) outperforms the biotech industry in the past year and the momentum is anticipated to continue in 2023 as well.
First Wave (FWBI) IND Filing Under FDA's Review, Stock Up
by Zacks Equity Research
First Wave's (FWBI) stock gains as FDA reviews its IND amendment for the planned phase II study of an enhanced enteric microgranule delivery formulation of adrulipase.
Biogen (BIIB) Partner Eisai Seeks Nod for Lecanemab in Japan
by Zacks Equity Research
Biogen's (BIIB) partner Eisai files a marketing authorization application for lecanemab for treating early Alzheimer's disease in Japan.
Are Medical Stocks Lagging Acer Therapeutics (ACER) This Year?
by Zacks Equity Research
Here is how Acer Therapeutics Inc. (ACER) and Syndax Pharmaceuticals (SNDX) have performed compared to their sector so far this year.
Roche (RHHBY) Gets EU Approval for Xofluza in New Patient Base
by Zacks Equity Research
The European Commission approves Roche's (RHHBY) Xofluza for treating uncomplicated influenza and post-exposure prophylaxis of influenza in children aged one year and above.
ETON Up as FDA Accepts NDA for Dehydrated Alcohol Injection
by Zacks Equity Research
Eton (ETON) gains as the its new drug application (NDA) for dehydrated alcohol injection for methanol poisoning is accepted for review by the FDA.
Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $25.62, marking a -1.16% move from the previous day.
Biogen's (BIIB) Partner Eisai Files MAA for Lecanemab in Europe
by Zacks Equity Research
Biogen's (BIIB) partner Eisai files a marketing authorization application to the European Medicines Agency for lecanemab for treating early Alzheimer's disease in Europe.
bluebird (BLUE) Updates on Progress With Zynteglo, 2023 Outlook
by Zacks Equity Research
bluebird bio, Inc. (BLUE) updates on the launch of gene therapy Zynteglo and provides cash burn guidance for 2023.
Editas (EDIT) Dips on Portfolio Reprioritization, To Cut Jobs
by Zacks Equity Research
Editas (EDIT) enters a restructuring and portfolio reprioritization to focus on hemoglobinopathies and in vivo gene editing. The company is to reduce its workforce by almost 20%. Shares fall.
Ultragenyx (RARE) Posts Preliminary '22 Results, Gives '23 View
by Zacks Equity Research
Ultragenyx (RARE) reports preliminary product revenues for its marketed drugs, Crysvita, Mepsevii and Dojolvi for the full year 2022. The company issues product revenue guidance for 2023.
Exelixis (EXEL) Announces Preliminary Q4 and 2022 Results
by Zacks Equity Research
Exelixis (EXEL) reports preliminary revenues for the fourth quarter and 2022. It also provides guidance for 2023 and pipeline updates.
Alnylam (ALNY) Posts Strong Preliminary Revenues for 4Q & FY22
by Zacks Equity Research
Alnylam (ALNY) reports strong preliminary product revenues for its marketed drugs, Onpattro, Amvuttra, Givlaari and Oxlumo for the fourth quarter and full year of 2022.
FATE To End Janssen Deal and Prioritize Pipeline Development
by Zacks Equity Research
FATE decides not to continue its collaboration and option agreement with Janssen. The company also conducts a strategic review.
FDA Accepts AstraZeneca (AZN), Sanofi's RSV Antibody BLA
by Zacks Equity Research
The FDA's decision on AstraZeneca (AZN)/Sanofi's (SNY) regulatory filing, seeking approval for using their RSV antibody in all infants, is expected in third-quarter 2023.
Roche's (RHHBY) Cancer Drug Glofitamab Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts and grants priority review to Roche's (RHHBY) biologics license application for glofitamab to treat relapsed or refractory large B-cell lymphoma. The decision is due on Jul 1, 2023.
Geron (GERN) Up on Imetelstat Data on Myelodysplastic Syndromes
by Zacks Equity Research
Geron (GERN) posts positive top-line data from the phase III IMerge study investigating its lead candidate, imetelstat for treating lower risk myelodysplastic syndromes. Shares up.
Phathom (PHAT) Down on Regulatory Update on Vonoprazan NDA
by Zacks Equity Research
Phathom Pharmaceuticals, Inc. (PHAT) declines as the FDA decides to not take any action on Phathom's new drug application (NDA) for vonoprazan for treating erosive esophagitis.
VERA Dips Despite Positive Data From IgA Nephropathy Study
by Zacks Equity Research
VERA posts positive top-line data from the phase IIb ORIGIN study evaluating atacicept for the treatment of IgA nephropathy.
Deciphera (DCPH) Issues Strategic & Corporate Outlook for 2023
by Zacks Equity Research
Deciphera (DCPH) provides a strategic outlook and planned corporate milestones for 2023. The company also posts preliminary fourth-quarter and 2022 revenues.
Wall Street Analysts Believe Syndax (SNDX) Could Rally 44%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Syndax (SNDX) points to a 43.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why Momentum in Syndax (SNDX) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Syndax (SNDX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
GSK's New Drugs and Pipeline Hold the Key to Growth in 2023
by Zacks Equity Research
GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion.